Authors: Andrew D Hardie William J Rieter Marques L Bradshaw Leonie L Gordon Matthew A Young Thomas E Keane
Publish Date: 2013/04/18
Volume: 31, Issue: 6, Pages: 1327-1332
Abstract
To preliminarily evaluate the potential for an improvement in diagnostic performance by a combined interpretation of In111 capromab pendetide single photon emission computed tomography SPECT including computed tomography CT image fusion with magnetic resonance diffusionweighted imaging MRDWI for identifying prostate cancer in pelvic lymph nodes thru correlation with histopathologyThis institutional approved retrospective study identified patients with available histopathology of lymph nodes removed at the time of radical prostatectomy and who had undergone staging with In111 capromab pendetide SPECTCT and/or pelvic MRI including DWI The performance of In111 capromab pendetide SPECT for identifying malignant lymph nodes was assessed Subsequently a combined reading of In111 capromab pendetide SPECT and prostate MRI with DWI was performed and the performance assessed18 patients underwent In111 capromab pendetide SPECTCT Of these 12 patients had also undergone imaging with MRDWI In111 capromab pendetide SPECTCT had a sensitivity of 400 and specificity of 967 for identification of malignant lymph nodes However In111 capromab pendetide SPECTCT combined with MRI with DWI had a sensitivity of 889 and specificity of 985 The addition of MRDWI to the interpretation of In111 capromab pendetide SPECTCT may increase the sensitivity for detecting malignant lymph nodes in prostate cancer Future prospective evaluation of combined In111 capromab pendetide SPECTCT and MRDWI is indicated and may improve clinical evaluation of nodal disease in prostate cancer
Keywords: